Wooshin Venture Investment
VC Fund
Seoul, South Korea
Wooshin Venture Investment is a VC fund in Seoul focused on Biotechnology and Pharmaceutical. Wooshin Venture Capital is the venture capital arm of Asia Cement Co. Ltd which invests in various range of sectors.
- Total investments:
- 33
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Wooshin Venture Investment invests in
Stages Wooshin Venture Investment invests in
Countries Wooshin Venture Investment invests in
Round sizes
Round size
- Series A
- $1.7M–$14M
- Series B
- $8.9M–$25M
- Series C
- $17M–$30M
Investment Focus
Industry
- Biotechnology 7 (21%)
- Pharmaceutical 6 (18%)
- Finance 4 (12%)
- Medical 3 (9%)
- Medical Device 3 (9%)
Stage
- Series B 12 (36%)
- Series A 11 (33%)
- Series C 5 (15%)
- Venture - Series Unknown 2 (6%)
- Seed 1 (3%)
Country
- South Korea 21 (64%)
- Singapore 2 (6%)
- United States 2 (6%)
- Malaysia 1 (3%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Ark is an AI-based early screening company focused on identifying and preventing complications associated with chronic diseases, developing and supplying advanced medical AI solutions that enable early detection, risk assessment, and proactive disease management to support healthcare providers in delivering more precise and timely care. | $13.5M / Series A / Mar 05, 2026 | ||
| Goi provides funeral service support solutions that enables organizations to manage employee welfare and memorial arrangements efficiently. The company delivers an integrated suite of services, including real-time funeral coordination, cost control, customized memorial products, nationwide delivery, administrative assistance, and transparentpricing. This approach allows corporations and institutions to optimize employee benefit programs while ensuring families receive accessible, reliable, and dignified end-of-life services, reducing both financial burden and operational complexity. | $6.1M / Series A / Dec 01, 2025 | ||
| IMBiologics is a biotechnology company that develops antibody-based drug candidates for diseases such as cancer and immune-related conditions. It conducts research and development using its own platforms to discover new therapeutic molecules. | $29.5M / Series C / Oct 14, 2025 | ||
| Z Enterprise is a finance and management firm that offers corporate financing, tax automation services, and computer and mobile apps. | $19.2M / Series C / Jun 09, 2025 | ||
| Dotter is a manufacturing company that designs and produces biodegradable optical coherence tomography devices to diagnose and treat cardiovascular diseases. The company also develops next-generation OCT equipment, an optical imaging device that can create a synergy effect when inserting stents. | $7K / Dec 27, 2024 | ||
| Dotter is a manufacturing company that designs and produces biodegradable optical coherence tomography devices to diagnose and treat cardiovascular diseases. The company also develops next-generation OCT equipment, an optical imaging device that can create a synergy effect when inserting stents. | $9.8M / Series B / Dec 27, 2024 | ||
| VESSL AI enables machine learning teams to develop state-of-the-art models at scale without the complex and repetitive process of setting up pipelines and infrastructures.In addition to a centralized dashboard and workflow management, VESSL AI offers enterprise-grade infrastructure equipped with automated resource provisioning, and powerfultraining modes with automated hyperparameter optimization and multi-node distributed training. | $12.2M / Series A / Oct 07, 2024 | ||
| Paywatch offers a platform that allows employees to access their earnings before payday anytime. | $13.8M / Series A / Jun 24, 2024 | ||
| Paywatch is a fintech company offering an Earned Wage Access (EWA) platform. It allows employees to access their earned salary before payday as a financial wellness benefit. The company also provides employee financial services like benefits, payments, and wage-linked solutions for employers and workers. | $14.4M / Series A / Jun 24, 2024 | ||
| Mediintech develops smart endoscopes for the digestive system. | $14.7M / Series B / May 13, 2024 | ||
| See all 33 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does Wooshin Venture Investment invest in?
Wooshin Venture Investment invests primarily in Biotechnology, Pharmaceutical and Finance startups, most often at Series B and Series A stage. Most of the 33 investments tracked by Shizune back companies in South Korea. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Wooshin Venture Investment's check size?
Wooshin Venture Investment typically joins rounds of $1.7M–$14M at Series A, $8.9M–$25M at Series B and $17M–$30M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Wooshin Venture Investment participates in.
When did Wooshin Venture Investment last invest?
The most recent investment recorded for Wooshin Venture Investment closed in Mar 2026. Shizune tracks 33 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
